Young-suk S. Lim
Expertise in
7
conditions

Young-suk S. Lim

Hepatology
Seoul, KR 
Expertise in
7
conditions
Seoul, KR 

Overview

Young-suk Lim is a Hepatologist practicing medicine in Seoul, Republic of Korea.

Mr. Lim is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Hepatitis B, Hepatitis, Liver Cancer, Liver Transplant, and Hepatectomy.

He is actively involved in clinical research, co-authoring 318 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hepatology

Gender

Male

Locations

Seoul, Republic of Korea
Other Locations
Songpa, Republic of Korea
Jungnam, Republic of Korea
Ulsan, Republic of Korea
Songnam, Republic of Korea
Gyeonggi-do, 449728, Republic of Korea
Busan, Republic of Korea
Daejeon, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Treatment Response in Chronic Hepatitis B Participants With and Without Nucleos(t)Ide Therapy Who Have Participated in a Previous Bepirovirsen Treatment Study
A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Treatment Response in Chronic Hepatitis B Participants With and Without Nucleos(t)Ide Therapy Who Have Participated in a Previous Bepirovirsen Treatment Study
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2026
Intervention Type: Drug
Study Drug: GSK3228836
Study Phase: Phase 2
A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection
A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection
Enrollment Status: Completed
Publish Date: April 29, 2026
Intervention Type: Drug
Study Drugs: AB-729, Peg-IFN?-2a
Study Phase: Phase 2
A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.
A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Other, Biological
Study Phase: Phase 1
A Multinational, Multicenter, Open-label, Randomized Controlled Trial to Investigate the Effectiveness of Tenofovir Alafenamide in Reducing Clinical Events in Chronic Hepatitis B Patients Beyond Treatment Indications by Current Guidelines
A Multinational, Multicenter, Open-label, Randomized Controlled Trial to Investigate the Effectiveness of Tenofovir Alafenamide in Reducing Clinical Events in Chronic Hepatitis B Patients Beyond Treatment Indications by Current Guidelines
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drug: Tenofovir Alafenamide
Study Phase: Phase 4
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
Switching From Tenofovir Disoproxil Fumarate(TDF) to Tenofovir AlaFenamide(TAF) vs. Maintaining TDF Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir or Entecavir
Switching From Tenofovir Disoproxil Fumarate(TDF) to Tenofovir AlaFenamide(TAF) vs. Maintaining TDF Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir or Entecavir
Enrollment Status: Completed
Publish Date: March 29, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Phase Ⅲ, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks
A Phase Ⅲ, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks
Enrollment Status: Unknown
Publish Date: January 27, 2020
Intervention Type: Drug
Study Drugs: Besifovir, Tenofovir
Study Phase: Phase 3
Randomized Trial Comparing Sorafenib and Transarterial Chemoembolization Plus External Beam Radiotherapy in Patients With Hepatocellular Carcinoma Showing Macroscopic Vascular Invasion
Randomized Trial Comparing Sorafenib and Transarterial Chemoembolization Plus External Beam Radiotherapy in Patients With Hepatocellular Carcinoma Showing Macroscopic Vascular Invasion
Enrollment Status: Completed
Publish Date: September 18, 2017
Intervention Type: Radiation, Drug
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

318 Total Publications

Comparison of clinical practice guidelines for chronic hepatitis B: natural history classification and treatment initiation.
Comparison of clinical practice guidelines for chronic hepatitis B: natural history classification and treatment initiation.
Journal: Clinical and molecular hepatology
Published: June 07, 2026

Frequently Asked Questions about Young-suk S. Lim

Is Young-suk S. Lim a top-rated expert for Hepatitis B?

MediFind is an objective health platform that identifies experts based on real-world data. Young-suk S. Lim is classified as an Elite expert for Hepatitis B, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Young-suk S. Lim specialize in?

While Young-suk S. Lim is a Hepatology, they have specific expertise in Hepatitis B, Hepatitis, and Liver Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hepatology.

Does Young-suk S. Lim participate in research or clinical trials?

Yes. Young-suk S. Lim has published 318 articles and abstracts on conditions like Hepatitis B. You can view a list of Young-suk S. Lim's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lim's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile